The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

Scientists are probing woolly mammoth and Neanderthal genetic codes for new compounds as today’s drugs lose potency.

Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

A groundbreaking antibiotic discovery might finally tip the balance in the global fight against drug-resistant bacteria.

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

For small molecule drugs (chemical compounds that are usually pills, e.g. empagliflozin [Jardiance]), prices are negotiated at year 7 and take effect 9 years after FDA approval. For biologics ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up ...

Tell us about the product or service that Inductive Bio offers.

One route has been the identification of antimicrobial chemical weaponry in Nature as small-molecule natural products were observed to have clinically useful antibacterial activity. Among these ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...